211 related articles for article (PubMed ID: 32155324)
1. Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.
Kellner F; Keil A; Schindler K; Tschongov T; Hünninger K; Loercher H; Rhein P; Böhmer SA; Böhmer FD; Müller JP
J Cell Mol Med; 2020 Apr; 24(8):4668-4676. PubMed ID: 32155324
[TBL] [Abstract][Full Text] [Related]
2. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
[TBL] [Abstract][Full Text] [Related]
3. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
[TBL] [Abstract][Full Text] [Related]
4. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
5. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
[TBL] [Abstract][Full Text] [Related]
6. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
Yamawaki K; Shiina I; Murata T; Tateyama S; Maekawa Y; Niwa M; Shimonaka M; Okamoto K; Suzuki T; Nishida T; Abe R; Obata Y
Sci Rep; 2021 Nov; 11(1):22678. PubMed ID: 34811450
[TBL] [Abstract][Full Text] [Related]
7. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
[TBL] [Abstract][Full Text] [Related]
8. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.
Nabinger SC; Li XJ; Ramdas B; He Y; Zhang X; Zeng L; Richine B; Bowling JD; Fukuda S; Goenka S; Liu Z; Feng GS; Yu M; Sandusky GE; Boswell HS; Zhang ZY; Kapur R; Chan RJ
Leukemia; 2013 Feb; 27(2):398-408. PubMed ID: 23103841
[TBL] [Abstract][Full Text] [Related]
9. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
[TBL] [Abstract][Full Text] [Related]
10. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
11. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
12. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
Scheijen B; Ngo HT; Kang H; Griffin JD
Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
14. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Chougule RA; Kazi JU; Rönnstrand L
Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
[TBL] [Abstract][Full Text] [Related]
15. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
[TBL] [Abstract][Full Text] [Related]
16. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
[TBL] [Abstract][Full Text] [Related]
17. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.
Godfrey R; Arora D; Bauer R; Stopp S; Müller JP; Heinrich T; Böhmer SA; Dagnell M; Schnetzke U; Scholl S; Östman A; Böhmer FD
Blood; 2012 May; 119(19):4499-511. PubMed ID: 22438257
[TBL] [Abstract][Full Text] [Related]
18. Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.
Lin DC; Yin T; Koren-Michowitz M; Ding LW; Gueller S; Gery S; Tabayashi T; Bergholz U; Kazi JU; Rönnstrand L; Stocking C; Koeffler HP
Blood; 2012 Oct; 120(16):3310-7. PubMed ID: 22942183
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
[TBL] [Abstract][Full Text] [Related]
20. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]